A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects With Mild to Moderate Alzheimer's Disease

Trial Profile

A Randomized, Double Blind, Placebo-controlled Study to Evaluate the Impact of Low Doses of Nilotinib (Tasigna®) on Safety, Biomarkers and Clinical Outcomes in Subjects With Mild to Moderate Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2017

At a glance

  • Drugs Nilotinib (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 17 Jan 2017 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
    • 17 Jan 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
    • 17 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top